Royal Bank of Canada
RNA

Royal Bank of Canada’s Atrium Therapeutics RNA Stock Holding History

Royal Bank of Canada’s Portfolio RNA Stock Details RNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$477K Buy
+35,698
New +$502K ﹤0.01% 4180

Other funds holding RNA

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TAL
TIG Advisors LLC New York $2.16B AUM 72.99% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
OCAI
O'Connor Alternative Investments New York $1.17B AUM
SC
Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Royal Bank of Canada's RNA Position: Q1 2026 in Review

Royal Bank of Canada opened a new position in Atrium Therapeutics (RNA) in Q1 2026: 35,698 shares worth $477K. The stake represents ﹤0.01% of the portfolio and ranks #4180 among its holdings.

162 funds tracked by Wall St. Rank hold RNA as of Q1 2026.

  • Royal Bank of Canada held 35,698 shares of Atrium Therapeutics worth $477K as of Q1 2026.
  • Atrium Therapeutics was a new Royal Bank of Canada position in Q1 2026.
  • Atrium Therapeutics made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #4180 holding.
  • 162 funds tracked by Wall St. Rank held Atrium Therapeutics as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.